Page last updated: 2024-11-13

sbi-0206965

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SBI-0206965: inhibits ULK1 kinase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92044402
CHEMBL ID4128069
SCHEMBL ID17544844
MeSH IDM000610726

Synonyms (34)

Synonym
S7885
CS-5016
AC-32934
HY-16966
sbi-0206965
1884220-36-3
sbi0206965
sbi 0206965
EX-A747
SCHEMBL17544844
AKOS027328490
2-({5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}oxy)-n-methylbenzamide
mfcd29472244
2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]oxy]-n-methyl-benzamide
sbi-0206965, >=98% (hplc)
EDJ ,
2-({5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}oxy)-n-methylbenzene-1-carboximidic acid
BCP23859
2-((5-bromo-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)oxy)-n-methylbenzamide
sbi0206965; sbi 0206965
BCP29511
us10266549, example 88
bdbm379177
us10266549, example 171a
2-(5-bromo-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-yloxy)-n-methylbenzamide
CCG-269603
A900828
2-[5-bromo-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]oxy-n-methylbenzamide
AS-56287
CHEMBL4128069
nsc-784816
nsc784816
gtpl11339
BS170577

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"SBI-0206965 has adequate brain permeability but low relative oral bioavailability which may be due to rapid hepatic metabolism, likely catalyzed by CYP3A enzymes."( Brain pharmacokinetics and metabolism of the AMP-activated protein kinase selective inhibitor SBI-0206965, an investigational agent for the treatment of glioblastoma.
DasGupta, B; Desai, JM; Desai, PB; Gawali, MV; Gudelsky, GA; Karve, AS; Sallans, L; Seibel, W, 2022
)
2.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase ULK1Homo sapiens (human)IC50 (µMol)0.24780.00290.14210.7850AID1494457; AID1512688; AID1682982; AID1682983; AID1706000
Serine/threonine-protein kinase ULK2Homo sapiens (human)IC50 (µMol)1.69180.00110.82224.5780AID1494458; AID1512689; AID1682984; AID1682986; AID1706001
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein localizationSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySerine/threonine-protein kinase ULK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection regenerationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection developmentSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase ULK1Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of protein lipidationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK1Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK2Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK2Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK2Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK2Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
axonSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
omegasome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
Atg1/ULK1 kinase complexSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1682985Binding affinity to recombinant human ULK1 assessed as change in melting temperature at 10 uM by thermal shift assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1705982Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1682991Inhibition of Myc-tagged ULK1 (unknown origin) expressed in HEK293T cells cotransfected with wild-type Flag tagged Beclin-1 assessed as decrease in pBeclin1 Ser15 at 10 uM measured after 1 hr by Western blot analysis relative to control2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1705981Inhibition of recombinant human ULK1 at 10 uM preincubated for 60 mins followed by substrate addition and measured after 30 mins by ADP-glo assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1683010Reduction in autophagosome accumulation in human MDA-MB-468 cells at 10 uM by transmission electron microscopic analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1682982Inhibition of recombinant human ULK1 (1-649) expressed in Sf9 cells using myelin basic protein as substrate by ADP-glo assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1682983Inhibition of ULK1 (unknown origin) expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1512689Inhibition of ULK2 (unknown origin)2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.
AID1682992Inhibition of Myc-tagged ULK1 (unknown origin) expressed in HEK293T cells cotransfected with wild-type Flag tagged Vps34 assessed as decrease in pVPS34 Ser249 at 10 uM measured after 1 hr by Western blot analysis relative to control2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1706001Inhibition of ULK2 (unknown origin)2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1705986Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1737701Inhibition of recombinant human GST-tagged AMPK alpha1/beta1/gamma1 expressed in African green monkey COS7 cells assessed as reduction in AMPK beta 1 S108 phosphorylation incubated for 10 mins by [gamma 32-P]-ATP based radiometric scintillation counting a2020European journal of medicinal chemistry, Jul-01, Volume: 197Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.
AID1705985Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1683000Cytotoxicity against human MDA-MB-468 cells measured after 72 hrs by Celltiter-Glo assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1683009Inhibition of starvation-induced autophagic flux in human MDA-MB-468 cells expressing tandem-labelled mCherryEGFP-LC3 chimeric protein at 10 uM measured after 18 hrs in EBSS media by flow cytometry (Rvb >90%)2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1494458Inhibition of GST-tagged ULK2 (unknown origin)2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
UNC-51-like Kinase 1: From an Autophagic Initiator to Multifunctional Drug Target.
AID1705983Antiproliferative activity against human U937 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1705984Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 24 hrs by MTT assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1494457Inhibition of GST-tagged ULK1 (unknown origin)2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
UNC-51-like Kinase 1: From an Autophagic Initiator to Multifunctional Drug Target.
AID1682986Inhibition of ULK2 (unknown origin) expressed in HEK293T cells incubated for 2 hrs by NanoBRET assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
AID1512688Inhibition of FLAG-tagged ULK1 (unknown origin) expressed in HEK293T cells using GST-labelled Atg101 as substrate in presence of gamma-[32]P-ATP2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.
AID1706000Inhibition of ULK1 (unknown origin) by 32P-ATP radio active assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer.
AID1682984Inhibition of recombinant human ULK2 (1 to 478 residues) expressed in Sf9 cells using myelin basic protein as substrate by ADP-glo assay2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (50.00)24.3611
2020's11 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]